Dr. Vijay Koka has been a valued member of Renal Specialists of Houston since 2007. He completed his fellowship in Nephrology at Baylor College of Medicine and holds a Master’s degree in Public Health from Harvard University. A published researcher in renowned medical journals such as Circulation and Nephrology, Dr. Koka serves as one of our principal investigators in our clinical research efforts. He primarily cares for patients in the Southeast/Pasadena area and serves as the Medical Director at Fresenius Kidney Care Clear Lake Dialysis Facility.
PROFESSIONAL/ACADEMIC APPOINTMENTS
- Volunteer Faculty, Baylor College of Medicine 2007 - 2021
- Hospitalist, Meritcare Hospital North Dakota 2002 - 2004
RENAL FELLOWSHIP
- Baylor College of Medicine, Houston Texas 2004 - 2007
RESIDENCY
- University of North Dakota, Fargo ND 1999 – 2002
- National University of Singapore, Research Student 1997 – 1998
- Medwin Hospital, Hyderabad India 1997
- Mediciti Hospital, Hyderabad India 1996
POSTGRADUATE
- Masters in Public Health, Harvard University School of Public Health 1998 - 1999
MEDICAL SCHOOL
- Christian Medical College, Vellore India 1990 – 1996
- Medicine and Surgery
BOARD CERTIFICATION
- American Board of Internal Medicine
- American Board of Internal Medicine Diplomate in Nephrology
AREAS OF CLINICAL INTEREST
- Hypertension
- Vasculitis and Glomerulonephritis
- Chronic Kidney Disease
- Dialysis
- Dialysis Access Management
PUBLICATIONS/RESEARCH
- Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY. Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation. 2006 March 14;113(10):1353-60.
- Wang W. Koka V. Lan HY. Transforming growth factor-beta and Smad signaling in kidney diseases. Nephrology (Carlton).2005 Feb;10(1):48-56.
- Potti A, Ganti AK, Tuchman SA, Sholes K, Langness E, KokaV, Koch M. HER-2/neu and CD117 (c-kit) over expression in patients with pesticide exposure and extensive stage small cell carcinoma (ESSCLC). J Carcinog, 2005 June 9;4-8.
- Potti A, Forseen SE, Koka VK, Pervez H, Koch M, Fraiman G.Mehdi SA, Levitt R. Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest.2004;22(4):537-44.
- Koka V, Potti A, Forseen SE, Pervez H, Fraiman GN, Koch M.Levitt R. Role of HER 2/neu over expression and clinical determinants of early mortality in glioblastoma multiforme.Am J Clin Oncol.2003 Aug;26(4):332-5.
- Ganti AK, Potti A, Koka VK, Pervez H, Mehdi SA. Myeloproliferative syndromes and the associated risk of
- coronary artery disease. Thromb Res.2003 May 1;110(2,3)83-6.
- Abdel-Raheem MM, Potti A, Tadros S. Koka V, Hanekom D,Fraiman G, Danielson BD. Effect of low-molecular-weight heparin on potassium homeostasis. Pathophysiol Haemost Thromb.2002 May-June;32(3):107-10.
- Froseen SE, Potti A, Koka V, Koch M, Fraiman G, Levitt R. Identification and relationship of HER-2/neu over expression to short term mortality in primary malignant brain tumors. Anticancer Res. 2002 May-June;22(3):1599-602.
